Table 2.
Summary of clinical features and treatment outcomes of patients with primary intraocular lymphoma treated with intravitreal and systemic high‐dose methotrexate (MTX)
| No. | Age, years | Sex | Disease type | Time to diagnosis, months | Involved eye | Cytology | FCM | PCR | IL‐10/IL‐6 | Times of IV‐MTX | Ocular relapse (months) | CNS progression (months) | Outcomes | Follow‐up period, months | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intravitreal and systemic high‐dose MTX | 1 | 69 | F | Mixed | 4 | R | − | − | + | >1 | 6 | − | − | Alive in CR | 75+ |
| 2 | 72 | F | Vitreous | 4 | R | + | N/A | N/A | >1 | 4 | + (14) | − | Died from unknown cause while in 2nd ocular CR | 35 | |
| L | − | + | + | >1 | 4 | ||||||||||
| 3 | 68 | M | Vitreous | 9 | R | + | N/A | N/A | >1 | 4 | − | + (22) | Died from CNS disease 9 months after initial CNS progression | 31 | |
| L | + | + | + | >1 | 4 | ||||||||||
| 4 | 53 | M | Vitreous | 5 | L | − | − | + | ≤1 | 2 | − | − | Alive in CR | 38 | |
| 5 | 72 | M | Mixed | 18 | R | + | + | − | >1 | 5 | − | − | Alive in CR | 37+ | |
| L | + | − | − | >1 | 5 | ||||||||||
| 6 | 78 | F | Mixed | 7 | R | − | + | − | >1 | 5 | − | + (19) | Lost to follow‐up in 2nd PR (CNS) with salvage HD‐MTX regimen | 21 | |
| L | + | + | − | >1 | 8 | ||||||||||
| 7 | 46 | F | Vitreous | 11 | R | + | + | − | >1 | 4 | − | − | Alive in CR | 28+ | |
| 8 | 63 | M | Vitreous | 13 | R | − | + | − | >1 | 5 | − | + (18) | Alive in 2nd PR (CNS) with salvage HD‐MTX regimen | 24+ | |
| L | N/A | N/A | N/A | N/A | 5 | ||||||||||
| 9 | 61 | F | Vitreous | 16 | R | + | + | + | >1 | 5 | + (15) | − | Alive in CR | 21+ | |
| L | + | + | + | >1 | 6 | ||||||||||
| 10 | 78 | F | Vitreous | 4 | R | + | + | + | >1 | 5 | − | + (11) | Alive in 2nd CR (CNS) with salvage radiation therapy | 20+ | |
| L | N/A | N/A | N/A | N/A | 5 |
No contralateral relapse was observed. CNS, central nervous system; CR, complete remission; F, female; FCM, flow cytometry; HD‐MTX, high‐dose methotrexate; IV‐MTX, intravitreal methotorexate; L, left; M, male; N/A, not available; PR, partial response; R, right.